263 related articles for article (PubMed ID: 11752034)
1. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease.
Kielstein JT; Böger RH; Bode-Böger SM; Frölich JC; Haller H; Ritz E; Fliser D
J Am Soc Nephrol; 2002 Jan; 13(1):170-176. PubMed ID: 11752034
[TBL] [Abstract][Full Text] [Related]
2. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes.
Tarnow L; Hovind P; Teerlink T; Stehouwer CD; Parving HH
Diabetes Care; 2004 Mar; 27(3):765-9. PubMed ID: 14988299
[TBL] [Abstract][Full Text] [Related]
3. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.
Kielstein JT; Böger RH; Bode-Böger SM; Schäffer J; Barbey M; Koch KM; Frölich JC
J Am Soc Nephrol; 1999 Mar; 10(3):594-600. PubMed ID: 10073610
[TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients.
Fleck C; Janz A; Schweitzer F; Karge E; Schwertfeger M; Stein G
Kidney Int Suppl; 2001 Feb; 78():S14-8. PubMed ID: 11168976
[TBL] [Abstract][Full Text] [Related]
5. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study.
Fliser D; Kronenberg F; Kielstein JT; Morath C; Bode-Böger SM; Haller H; Ritz E
J Am Soc Nephrol; 2005 Aug; 16(8):2456-61. PubMed ID: 15930091
[TBL] [Abstract][Full Text] [Related]
6. Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro evidence of significant protein binding.
Kielstein JT; Böger RH; Bode-Böger SM; Martens-Lobenhoffer J; Lonnemann G; Frölich JC; Haller H; Fliser D
Clin Nephrol; 2004 Oct; 62(4):295-300. PubMed ID: 15524060
[TBL] [Abstract][Full Text] [Related]
7. Nitric oxide synthase inhibitors and hypertension in children and adolescents.
Goonasekera CD; Rees DD; Woolard P; Frend A; Shah V; Dillon MJ
J Hypertens; 1997 Aug; 15(8):901-9. PubMed ID: 9280214
[TBL] [Abstract][Full Text] [Related]
8. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure.
Nanayakkara PW; Teerlink T; Stehouwer CD; Allajar D; Spijkerman A; Schalkwijk C; ter Wee PM; van Guldener C
Kidney Int; 2005 Nov; 68(5):2230-6. PubMed ID: 16221223
[TBL] [Abstract][Full Text] [Related]
9. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
Busch M; Fleck C; Wolf G; Stein G
Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
[TBL] [Abstract][Full Text] [Related]
10. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients.
Kumagai H; Sakurai M; Takita T; Maruyama Y; Uno S; Ikegaya N; Kato A; Hishida A
Am J Kidney Dis; 2006 Nov; 48(5):797-805. PubMed ID: 17059999
[TBL] [Abstract][Full Text] [Related]
11. The differences of asymmetric dimethylarginine removal by different dialysis treatments.
Zhang DL; Liu J; Liu S; Zhang Y; Liu WH
Ren Fail; 2010; 32(8):935-40. PubMed ID: 20722560
[TBL] [Abstract][Full Text] [Related]
12. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects.
Kielstein JT; Bode-Böger SM; Frölich JC; Ritz E; Haller H; Fliser D
Circulation; 2003 Apr; 107(14):1891-5. PubMed ID: 12681993
[TBL] [Abstract][Full Text] [Related]
13. Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with Type 2 diabetes and albuminuria.
Krzyzanowska K; Mittermayer F; Shnawa N; Hofer M; Schnabler J; Etmüller Y; Kapiotis S; Wolzt M; Schernthaner G
Diabet Med; 2007 Jan; 24(1):81-6. PubMed ID: 17227328
[TBL] [Abstract][Full Text] [Related]
14. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach.
Ravani P; Tripepi G; Malberti F; Testa S; Mallamaci F; Zoccali C
J Am Soc Nephrol; 2005 Aug; 16(8):2449-55. PubMed ID: 15944335
[TBL] [Abstract][Full Text] [Related]
15. Asymmetric dimethylarginine in homocystinuria due to cystathionine beta-synthase deficiency: relevance of renal function.
Wilcken DE; Wang J; Sim AS; Green K; Wilcken B
J Inherit Metab Dis; 2006 Feb; 29(1):30-7. PubMed ID: 16601865
[TBL] [Abstract][Full Text] [Related]
16. Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease.
Wang D; Strandgaard S; Borresen ML; Luo Z; Connors SG; Yan Q; Wilcox CS
Am J Kidney Dis; 2008 Feb; 51(2):184-91. PubMed ID: 18215696
[TBL] [Abstract][Full Text] [Related]
17. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients.
Zoccali C; Mallamaci F; Maas R; Benedetto FA; Tripepi G; Malatino LS; Cataliotti A; Bellanuova I; Böger R;
Kidney Int; 2002 Jul; 62(1):339-45. PubMed ID: 12081596
[TBL] [Abstract][Full Text] [Related]
18. Level of asymmetric dimethylarginine and carotid atherosclerosis in patients with chronic kidney disease.
Zhang WR; Hou FF; Ning JP; Yang XB; Wu Q; Tao LJ; Chen BM; Li HY; Chang L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):621-8. PubMed ID: 17062918
[TBL] [Abstract][Full Text] [Related]
19. Asymmetric dimethylarginine, homocysteine and renal function--is there a relation?
Siroká R; Trefil L; Rajdl D; Racek J; Rusnáková H; Cibulka R; Eiselt J; Filipovský J
Clin Chem Lab Med; 2005; 43(10):1147-50. PubMed ID: 16197312
[TBL] [Abstract][Full Text] [Related]
20. Relationship between asymmetric dimethylarginine plasma level and left ventricular mass in hemodialysis patients.
El Shahawy Y; Soliman Y; Rifaie A; Shenawy H; Behairy M; Mady G
Saudi J Kidney Dis Transpl; 2015 Jan; 26(1):26-33. PubMed ID: 25579712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
